Status:
COMPLETED
Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Lead Sponsor:
National Taiwan University Hospital
Conditions:
End-Stage Renal Disease
Osteoporosis
Eligibility:
All Genders
20-80 years
Phase:
PHASE4
Brief Summary
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women. However, its safety and efficacy in increasing bone mineral density in chronic peritoneal dialysis (PD) pat...
Detailed Description
Study Design The study is a prospective, randomized cross-over study. Fifty patients will be included. All participants are randomly allocated to either group 1 or group 2. Each group consists of 25 ...
Eligibility Criteria
Inclusion
- Have received maintenance PD for more than 3 months at National Taiwan University Hospital,
- Have high CPP level (≧50), and
- Have chest X-ray proven aortic calcification or coronary artery calcification proven before.
Exclusion
- Patients are excluded if they have any one of the following conditions:
- Had been hospitalized in recent 3 months due to severe comorbid diseases,
- Are hypersensitive to alendronate or any of its components,
- Have esophageal diseases
- Are not able to stand or sit upright for 30 minutes,
- Have refractory hypocalcemia, or
- Patients who are pregnant.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00261625
Start Date
August 1 2005
End Date
October 1 2007
Last Update
January 5 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.